Ilex/Sanofi Zyrkamine (mitoguazone) user fee deadline postponed; committee review to be rescheduled.
ILEX SUBMITS ADDITIONAL ZYRKAMINE DATA TO FDA, POSTPONING USER FEE DEADLINE from the decision date originally set for the end of April. Ilex said it is awaiting a determination of the new user fee date. Ilex submitted its NDA on Oct. 28 for accelerated approval of Zyrkamine (mitoguazone, methyl-glyoxal-bisguanylhydrazone) for treatment of patients with AIDS-related non-Hodgkin's lymphoma who have failed on another therapy.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth